Neuronetics, Inc. Raises $30 Million in Series E Financing MALVERN, PA--(Marketwire - May 16, 2011) - Neuronetics, Inc., maker of the NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy® System for the treatment of major depression*, announced today...

New Trial Data Confirm Clinical Effectiveness and Good Adherence Rates With NeuroStar TMS Therapy in Patients With Major Depressive Disorder Treated in a Real World Practice Setting HONOLULU, HI--(Marketwire - May 15, 2011) - Results of a Neuronetics-sponsored, multisite observational study of patients with major depressive disorder (MDD) treated with Neuronetics' NeuroStar...

Neuronetics Receives TiE50 Award for Technology Entrepreneurship MALVERN, PA--(Marketwire - May 9, 2011) - Neuronetics, Inc., maker of the NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy® System, has been selected by TiE Silicon Valley as a 2011 recipient...

New Data Show No Negative Long-Term Effect in Cognitive Function in Patients With Major Depressive Disorder Treated With NeuroStar TMS Therapy(R) HONOLULU, HI--(Marketwire - Apr 14, 2011) - In an open-label study of patients with major depressive disorder (MDD) who had not benefitted from prior antidepressant medication and were treated with...

Neuronetics Appoints Vice President of Health Policy and Government Relations MALVERN, PA--(Marketwire - March 2, 2011) - Neuronetics, Inc. today announced that Mary Hailey, an industry executive with more than 25 years of experience in designing and implementing healthcare...